U.S. court invalidates patent on Bristol hepatitis B drug
Feb 12 (Reuters) - A U.S. federal court has invalidated the patent on Bristol-Myers Squibb Co's Baraclude treatment for hepatitis B after a challenge from generic drugmaker Teva Pharmaceutical Industries Ltd, Bristol-Myers said on Tuesday.
"We are disappointed with the court's decision and believe it is incorrect," Bristol-Myers spokeswoman Laura Hortas said. She said her company is considering whether to appeal the ruling by the U.S. District Court in Delaware.
- Insight: How U.S. spying cost Boeing multibillion-dollar jet contract
- Exclusive: Secret contract tied NSA and security industry pioneer |
- With Fed out of the way, what's next on Wall Street?
- U.S. aircraft hit by gunfire in South Sudan as conflict worsens |
- Seagram chairman, WJC head Edgar Bronfman dead at 84